Abivax provides 2024 strategic outlook and lays out key milestones

 

• Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in moderately to severely active ulcerative colitis (UC)
• Formal process evaluating oral and injectable combination therapy candidates with obefazimod in UC has commenced; preclinical data to support decision-making on combination agent expected in 2H 2024
• Top-line data from long-term extension trial with 25mg obefazimod once-daily oral after one and two years of treatment expected to read-out in Q3 2024
• IND for Phase 2 trial of obefazimod in Crohn’s disease (CD) cleared; Abivax to consider protocol modifications based on FDA recommendations
• Obefazimod follow-on candidate selection expected in Q3 2024

https://www.biospace.com/article/releases/abivax-provides-2024-strategic-outlook-and-lays-out-key-milestones-over-next-12-months/